Home » Authors » Brady Huggett

Articles by Brady Huggett

Rigel Raises $31.5M To Move First Product Into Clinic In 2002

Jan. 18, 2002

By Brady Huggett

Maxim Begins Ceplene Phase III With Liver Metastases Patients

Jan. 18, 2002

By Brady Huggett

Rigel Raises $31.5M To Move First Product Into Clinic In 2002

Jan. 18, 2002

By Brady Huggett

Immunex’s Enbrel Continues Growth, Receives 4th Approval

Jan. 17, 2002

By Brady Huggett

Immunex’s Enbrel Continues Growth, Receives 4th Approval

Jan. 17, 2002

By Brady Huggett

Aderis Files For $100M IPO With Parkinson’s Product In Phase III

Jan. 15, 2002

By Brady Huggett

Aderis Files For $100M IPO With Parkinson’s Product In Phase III

Jan. 15, 2002

By Brady Huggett

Antigenics Raises $60M From Shelf For Oncophage Trials

Jan. 14, 2002

By Brady Huggett

Antigenics Raises $60M From Shelf For Oncophage Trials

Jan. 14, 2002

By Brady Huggett

Hyseq Buying Amgen Compound To Move First Product Into Clinic

Jan. 10, 2002

By Brady Huggett

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Nov. 27, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for November 27, 2024.
In muscular dystrophies, gene therapies race the clock
BioWorld
Since the isolation of the gene that causes Duchenne muscular dystrophy (DMD), scientists have progressed in understanding the mechanisms that lead to muscular...
Bridgebio, with FDA approval, faces Pfizer in ATTR
BioWorld
With the U.S. FDA approval of Attruby (acoramidis) for transthyretin amyloidosis with cardiomyopathy (ATTR-CM), Bridgebio Pharma Inc. is taking on an industry...
‘Evo’ AI can design complete genomes
BioWorld Science
The development of new machine learning tools like Alphafold and Rfdiffusion has allowed scientists to predict the structure of proteins and design them for drug...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.